Association of Polymorphic Markers of the TP53, MDM2, and CDKN1A Genes with the Risk of Ovarian Cancer

被引：0
|
作者：
P. K. Brenner
M. A. Kapralova
D. S. Khodyrev
S. V. Khokhlova
G. N. Khabas
A. V. Asaturova
Yu. V. Nosova
L. N. Kayumova
T. M. Zavarykina
机构：
[1] Emanuel Institute of Biochemical Physics,
[2] Russian Academy of Sciences,undefined
[3] Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of the Russian Federation,undefined
[4] Kulakov National Medical Research Center of Obstetrics,undefined
[5] Gynecology and Perinatology,undefined
[6] Sechenov First Moscow State Medical University (Sechenov University),undefined
来源：
Russian Journal of Genetics | 2022年 / 58卷
关键词：
ovarian cancer; polymorphic marker; cell cycle control; apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1154 / 1158
页数：4
相关论文
共 50 条
  • [21] Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
    Xiao, Mang
    Zhang, Lei
    Zhu, Xinhua
    Huang, Jun
    Jiang, Huifen
    Hu, Sunhong
    Liu, Yuehui
    BMC CANCER, 2010, 10
  • [22] Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
    Mang Xiao
    Lei Zhang
    Xinhua Zhu
    Jun Huang
    Huifen Jiang
    Sunhong Hu
    Yuehui Liu
    BMC Cancer, 10
  • [23] Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
    Maria Cabezas
    Lydia García-Quevedo
    Cintia Alonso
    Marta Manubens
    Yolanda Álvarez
    Joan Francesc Barquinero
    Santiago Ramón y Cajal
    Margarita Ortega
    Adoración Blanco
    María Rosa Caballín
    Gemma Armengol
    Scientific Reports, 9
  • [24] TP53 and p21 (CDKN1A) polymorphisms and the risk of systemic lupus erythematosus
    Macedo, Jacyara Maria Brito
    Silva, Amanda Lima
    Pinto, Amanda Chaves
    Landeira, Leandro Ferreira Lopes
    Portari, Elyzabeth Avvad
    Santos-Reboucas, Cintia Barros
    Klumb, Evandro Mendes
    ADVANCES IN RHEUMATOLOGY, 2023, 63 (01)
  • [25] TP53 and p21 (CDKN1A) polymorphisms and the risk of systemic lupus erythematosus
    Jacyara Maria Brito Macedo
    Amanda Lima Silva
    Amanda Chaves Pinto
    Leandro Ferreira Lopes Landeira
    Elyzabeth Avvad Portari
    Cintia Barros Santos-Rebouças
    Evandro Mendes Klumb
    Advances in Rheumatology, 63
  • [26] TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas
    Della Torre, G
    Pasquini, G
    Pilotti, S
    Alasio, L
    Civelli, E
    Cozzi, G
    Milella, M
    Salvetti, M
    Pierotti, MA
    Severini, A
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2000, 9 (01) : 41 - 46
  • [27] Activating TP53 by Dual Inhibition of MDMX and MDM2
    Steidl, Ulrich G.
    BLOOD, 2019, 134
  • [28] Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer
    Yoneda, Tomoko
    Kuboyama, Ayumi
    Kato, Kiyoko
    Ohgami, Tatsuhiro
    Okamoto, Kanako
    Saito, Toshiaki
    Wake, Norio
    ONCOLOGY REPORTS, 2013, 30 (01) : 25 - 34
  • [29] Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk
    Samuel, Nardin
    Id Said, Badr
    Guha, Tanya
    Novokmet, Ana
    Li, Weili
    Silwal-Pandit, Laxmi
    Borrsen-Dale, Anne-Lise
    Langerod, Anita
    Hudson, Thomas J.
    Malkin, David
    HUMAN MUTATION, 2017, 38 (03) : 265 - 268
  • [30] Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B
    José Luis Soto
    Carmen M Cabrera
    Salvio Serrano
    Miguel Ángel López-Nevot
    BMC Cancer, 5
12345